Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

por Perumal, Jai, Fox, Robert J., Balabanov, Roumen, Balcer, Laura J., Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily
Publicado 2019

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

por Brys, Miroslaw, Fanning, Laura, Hung, Serena, Ellenbogen, Aaron, Penner, Natalia, Yang, Minhua, Welch, Mackenzie, Koenig, Erica, David, Eric, Fox, Tara, Makh, Shavy, Aldred, Jason, Goodman, Ira, Pepinsky, Blake, Liu, YuTing, Graham, Danielle, Weihofen, Andreas, Cedarbaum, Jesse M.
Publicado 2019